Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for Chemotherapy-Induced Neutropenia in HNSCC
NCT06714266Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in neutropenia, sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence of grade >=3 neutropenia during chemotherapy at 2 years. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT06714266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714266.